Previous whole-cell patch-pipette studies showed that focal electrical stimulation of the subthalamic nucleus (STN) evokes a long-lasting complex excitatory postsynaptic currents (EPSC) and synaptically evoked bursts of action potentials in substantia nigra pars reticulata (SNR) neurons. Although synaptically evoked bursting may play a role in normal physiology, excessive burst firing correlates with symptoms of Parkinson's disease. We used patch-pipette recordings in rat brain slices to study the effects of baclofen on complex EPSCs and STN-induced burst firing in SNR neurons. Baclofen (1 lM) caused a reversible, 73% reduction in complex EPSCs, and this effect was blocked by the c-aminobutyric acid B antagonist CGP35348 (100 lM). Using the loosepatch method to record extracellular potentials, a lower concentration of baclofen (100 nM) inhibited STN-evoked bursts, while leaving spontaneous firing of action potentials less affected. We suggest that strategies that selectively inhibit burst firing in the SNR might have therapeutic potential in the treatment of Parkinson's disease.
Introduction
The substantia nigra pars reticulata (SNR) and the globus pallidus interna (GPI) comprise the major output nuclei of the basal ganglia. As such, these nuclei play important roles in basal ganglia physiology, which is largely concerned with the planning and execution of movement [1] . The rigidity, tremor, and bradykinesia seen in Parkinson's disease are attributed to an impaired basal ganglia function caused by dopamine depletion. Neurophysiological studies in rodents and primates have shown that experimentally induced parkinsonism is associated with excessive burst firing of action potentials in the SNR and GPI [2, 3] . Many studies have shown that an increased output from glutamatecontaining neurons in the subthalamic nucleus (STN) is the driving force behind excessive bursting in SNR and GPI neurons [4] . Thus, lesioning the STN has been shown to reduce burst firing in SNR neurons in rats made parkinsonian with intracerebral 6-hydroxydopamine treatment [5, 6] . In addition, high-frequency stimulation of the STN has been shown to reduce burst firing in SNR neurons and to improve symptoms in patients with Parkinson's disease [7] . These and other studies support the hypothesis that excessive activity in STN pathways to the SNR and GPI underlie symptoms of Parkinson's disease [8] .
Recent neurophysiological studies in rat brain slice preparations have shown that a single electrical stimulus delivered to the STN evokes a long-lasting excitatory current in SNR and GPI neurons [9, 10] . When recorded under voltage clamp, these glutamate-mediated complex excitatory postsynaptic currents (EPSCs) last 200-500 ms and consist of an initial monosynaptic EPSC followed by a series of late EPSCs superimposed on a slow inward shift in holding current. When recorded under current-clamp conditions, STN stimulation evokes a long-lasting EPSP that generates a burst of action potentials. Although synaptically generated bursts may play a role in normal physiology, excessive bursting by this mechanism could contribute to parkinsonism. Therefore, pharmacological strategies that quench synaptically generated burst firing may have therapeutic potential.
Our laboratory has shown previously that activation of gaminobutyric acid B (GABA B ) receptors causes presynaptic inhibition of glutamate-mediated EPSCs in STN and SNR neurons [11, 12] . Therefore, we were interested to find whether GABA B receptors play a role in modulating complex EPSCs and burst firing in SNR neurons. Using whole-cell and loose-patch recording techniques in rat brain slices, we delivered single stimuli to the STN to evoke complex EPSCs and bursts of action potentials in SNR neurons. Results show that the GABA B agonist, baclofen, is an effective inhibitor of complex EPSCs and stimulus-evoked bursts.
Materials and methods

Tissue preparation
All procedures were carried out in accordance with a protocol approved by Institutional Animal Care and Use Committee, the Portland Veterans Affairs Medical Center. Horizontal slices containing diencephalon and rostral midbrain were prepared from young Sprague-Dawley rats (post natal day 8-21; Harlan, Indianapolis, Indiana, USA) as described previously [11] . In brief, rats were euthanized by severing thoracic vessels under isoflurane anesthesia. Brains were rapidly removed and slices (400 mm) were cut with a vibratome in an ice-cold solution of the following composition (in mM): sucrose, 196; KCl, 2.5; MgCl 2 , 3.5; CaCl 2 , 0.5; NaH 2 PO 4 , 1.2; glucose, 20, and NaHCO 3 25 equilibrated with 95% O 2 and 5% CO 2 . A slice containing the STN and SNR was then placed on a supporting net and submerged in a continuously flowing solution (2 ml/min) of the following composition (mm): NaCl, 126; KCl, 2.5; CaCl 2 , 2.4; MgCl 2 , 1.2; NaH 2 PO 4 , 1.2; NaHCO 3 , 19; and glucose, 11 equilibrated with 95% O 2 and 5% CO 2 (pH 7.4) at 361C. Using a dissection microscope for the visual guidance, the SNR was identified 1-2 mm lateral to the substantia nigra zona compacta, whereas the STN was located as grey matter approximately 2.7 mm lateral to the midline and 2 mm rostral to the center of the SNR.
Electrophysiological recordings
Whole-cell recordings were made with pipettes with an initial resistance of 4-5 MO. Unless stated otherwise, internal pipette solution contained (in mM): cesium gluconate, 138; MgCl 2 , 2; CaCl 2 , 1; EGTA, 11; HEPES, 10; ATP, 1.5; and GTP, 0.3 (pH 7.3). Whole-cell membrane currents were amplified with an Axopatch-1D amplifier and recorded under voltage clamp at a holding potential of -70 mV. Data were acquired using a personal computer with a Digidata analog/digital interface and analyzed using the pCLAMP software (Molecular Devices, Axon Instruments, Foster City, California, USA). Membrane potentials have been corrected for the liquid junction potential (10 mV). In some experiments, membrane potentials were recorded extracellularly in the loose-patch configuration using pipettes that contained standard extracellular solution [13] . Loose-patch recordings were taken with a seal resistance typically five to 10 times the starting value of electrode resistance (3-8 MO).
Synaptic currents
Complex EPSCs and stimulus-evoked firing were evoked in SNR neurons using a bipolar stimulation electrode (2-4-MO impedance at 1000 Hz, 10 nA; Frederick Haer and Co., Bowdoin, Maine, USA) that was placed directly within the STN, as described previously [9] . In the continuous presence of picrotoxin (100 mM), rectangular pulses (0.1-ms duration) of constant current (50-400 mA) were delivered to the STN at an interval of 20-60 s. Complex EPSCs were quantified by measuring their integrated area using the pCLAMP 9 software (Molecular Devices).
Drugs
All drugs were dissolved into aqueous or dimethyl sulfoxide stock solutions, except picrotoxin. Stock solutions of drugs were diluted at least 1 : 1000 to the desired concentration in superfusate immediately before use. Dimethyl sulfoxide, diluted 1 : 1000 in artificial spinal fluid, had no effect on either holding current or synaptic currents. Approximately, 30 s was required for the drug solution to enter the recording chamber. Baclofen, picrotoxin, and CGP35348 (3aminopropyl-diethoxymethyl-phosphinic acid) were obtained from Tocris Cookson Inc. (Ellisville, Missouri, USA).
Data analysis
Numerical data in the text and error bars in figures are expressed as mean ± standard error of the mean. Paired data were analyzed with either one-way analysis of variance (ANOVA) with repeated measures (RM) or paired t-tests (Jandel Scientific, San Rafael, California, USA). Data not normally distributed were analyzed with the Mann-Whitney rank-sum test. A significant difference was accepted when the P value was of less than 0.05.
Results
GABA B receptor-mediated inhibition of complex excitatory postsynaptic currents
As we and others reported previously [9, 10] , a single electrical stimulus delivered to the STN evokes a longlasting, complex EPSCs in SNR neurons that is mediated by glutamate synaptic transmission. We have also shown that GABA B receptor stimulation causes presynaptic inhibition of glutamate-mediated EPSCs in the SNR and STN [11, 12] . Therefore, we proceeded to test whether GABA B receptors play a role in regulating the synaptic transmission that generates complex EPSCs. As shown in Fig. 1a , superfusing the slice with the GABA B agonist, baclofen, caused a concentration-dependent and reversible inhibition of the complex EPSC. Baclofen at 100 nM and 1 mM reduced the integrated area of the complex EPSC by 64 ± 4% (n = 5) and 73 ± 5% (n = 9), respectively (P < 0.01, paired t-test). The action of baclofen began within 1 min of perfusion and reached its peak effect within 5 min. After removing baclofen from the perfusate, the complex EPSC returned to the control value within 10-15 min. Figure 1b shows the average time-dependent effect of 1 mM of baclofen on the integrated area of complex EPSCs. When recorded with pipettes that contained K + instead of Cs + gluconate, baclofen (100 nM) caused a small, reversible outward current (40 ± 13 pA; n = 9), which agrees with the results of others [14] . Pretreatment of the slice with 100 mM CGP35348, a GABA B receptor blocker, antagonized the baclofen-dependent inhibition of complex EPSCs (Fig. 1c ). On average, 1 mM of baclofen reduced complex EPSCs by only 7 ± 7% in the presence of 100 mM of CGP35348 (n = 7; Fig. 1d ). These results show that GABA B receptors regulate synaptic transmission that generates complex EPSCs.
Baclofen suppresses evoked burst activity
It is now well established by our lab and others that complex EPSCs cause bursts of action potentials when recorded in current-clamp mode [9, 10] . Having Baclofen inhibits stimulus-evoked bursts Shen and Johnson 41 established that GABA B receptor stimulation suppresses complex EPSCs, we then tested the effect of baclofen on stimulus-evoked burst firing in SNR neurons recorded in loose-patch configuration. As shown in Fig. 2a , baclofen (100 nM) caused a reversible suppression of stimulusevoked action potentials, while also slowing spontaneous action potential discharge. Averaged data in Fig. 2b show that 100 nM of baclofen reduced the number of spikes measured up to 1 s after the stimulus from a control value of 19.3 ± 3.4 to 9.4 ± 1.3 spikes (n = 7; P < 0.01, one-way ANOVA with RM). Figure 1b also shows that this concentration of baclofen reduced the spontaneous firing rate from a control value of 8.5 ± 0.5 to 6.0 ± 0.5 Hz (n = 8; P < 0.01, one-way ANOVA with RM). We then normalized these data by expressing the effect of baclofen in terms of percentage of control values. Results in Fig. 2c show that baclofen caused a significantly greater reduction in stimulus-evoked spikes (52 ± 6% of control) compared with reduction in spontaneous firing rate (70 ± 3% of control; P < 0.05, Mann-Whitney rank-sum test). Thus, baclofen caused a preferential inhibition of stimulus-induced bursts compared with the inhibition of spontaneous activity.
Discussion
The present study shows that GABA B receptor activation effectively inhibits the complex EPSC that underlies synaptically generated burst firing in SNR neurons. We also showed that the GABA B agonist baclofen was more potent for inhibiting stimulus-evoked bursts compared with the inhibition of spontaneous firing of action potentials.
These results suggest that GABA B receptors regulate synaptic transmission in the subthalamonigral pathway.
Our studies also showed that baclofen evoked a small outward current in SNR neurons, which agrees with the results of others [14] . This hyperpolarizing influence would be expected to inhibit both evoked and spontaneous action potential discharge through a postsynaptic site of action. However, we showed that baclofen was more potent for inhibiting evoked spikes compared with spontaneous firing. In fact, we may have underestimated the selectivity of this action of baclofen because evoked spikes were counted up to 1 s after each stimulus, which would have included some spontaneous spikes and evoked spikes. The basis for this selective action of baclofen is likely related to the mechanism by which complex EPSCs and stimulus-evoked bursts are generated. Previous studies supported the hypothesis that complex EPSCs are polysynaptic phenomena that are generated by activation of recurrent glutamate collateral axons in the STN [9, 10] . As polysynaptic transmission is highly sensitive to inhibitors of synaptic function [15, 16] , it is likely that baclofen acts within the STN to inhibit complex EPSCs. Our current results agree with our previous studies showing that baclofen inhibits glutamate synaptic transmission by acting at presynaptic sites of action in the STN and SNR [11, 12] . Thus, the relative selectivity of baclofen for inhibition of evoked burst firing is likely due to inhibition of polysynaptic connections in the subthalamonigral pathway.
Increased SNR neuronal activity has been associated with normal limb movement [17] and cessation of saccadic eye movements [18] . Thus, the bursting firing pattern likely plays a role in normal physiology. However, excessive SNR burst firing in rodents has been associated with parkinsonism induced by neuroleptic agents [19] and by dopamine depleting agents, such as 6-hydroxydopamine [2, 20] . Thus, one may speculate that suppression of stimulus-induced bursts by baclofen might have therapeutic potential. However, a controlled clinical trial showed that some symptoms of Parkinson's disease were actually worsened by baclofen [21] . The fact that baclofen might worsen parkinsonism is not surprising when one considers that activation of GABA B receptors also hyperpolarizes dopamine neurons and suppresses dopamine release from nerve terminals [22, 23] . As GABA B receptors are widely expressed throughout the brain, it is doubtful that baclofen could exert the selectivity of action that would be needed to be clinically useful in the treatment of Parkinson's disease. However, other strategies aimed at disrupting SNR burst firing may be useful, such as high-frequency stimulation of the subthalamonigral pathway, which has been shown to disrupt complex EPSCs and stimulus-evoked burst firing in brain slice preparations [24, 25] .
Conclusion
GABA B receptor activation produces a relatively selective reduction in synaptically mediated burst discharges in SNR neurons. Agents that selectively inhibit burst firing in the SNR might useful in the treatment of Parkinson's disease. 
